Phase 3 randomized EORTC 1325-MG/KEYNOTE-054 study results: pembrolizumab versus placebo after complete resection in patients with high-risk stage III melanoma.
Authors
Khattak, ARobert, C
Blank, C
Mandala, M
Long, G
Atkinson, V
Dalle, S
Haydon, A
Lichinitser, M
Carlino, M
Sandhu, S
Larkin, J
Puig, S
Ascierto, P
Rutkowski, P
Schadendorf, D
Lorigan, Paul C
Ibrahim, N
Suciu, S
Eggermont, A
Affiliation
Fiona Stanley Hospital/University of Western Australia, Perth, AustraliaIssue Date
2018